Wight, Joel, Hamad, Nada, Campbell, Belinda A., Ku, Matthew, Lee, Kenneth, Rose, Hannah, Armytage, Tasman, Latimer, Maya, Lee, Hui-Peng, Lee, Sze-Ting, Dickinson, Michael, Khor, Richard, and Verner, Emma (2022) Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 52 (9). pp. 1609-1623.

PDF (Published Version) - Published Version Restricted to Repository staff only

 

4

1

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30–40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.

Actions (Repository Staff Only)

Item Control Page